Acuity Completes Enrollment in Phase II AMD Trial;
Begins Pilot Phase II Study in Diabetic Macular Edema
Acuity Pharmaceuticals said this week that it has completed patient enrollment in a phase II trial of its siRNA-based treatment for age-related macular degeneration. The company also said that it has begun testing the drug, called Cand5, in a pilot phase II study for diabetic macular edema.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
